ABVX
HEALTHCAREAbivax
Live · NASDAQ · May 9, Close
What's Moving ABVX Today?
No stock-specific AI insight has been generated for ABVX yet. Check back soon — insights are generated from recent news analysis.
52-Week Range
$126.54
Fundamentals
Trading
ABVX News
23 articles- Abivax Buys Back $90 Million in Royalties via $45 Million ADS Offering, Keeps Cash Runway to Q4 2027TipRanks·May 7, 2026
- ABIVAX (ABVX) Announces $90M Agreement to Repurchase Royalty CertificatesYahoo Finance·May 6, 2026
- Abivax Announces Repurchase of Royalty Certificates and Pricing of $45M (€38.5M) Offering of American Depositary SharesYahoo Finance·May 5, 2026
- Here is Why Abivax (ABVX) is One of the Best Up and Coming Stocks with Highest Upside PotentialYahoo Finance·May 1, 2026
- Abivax to Present Data on Obefazimod at Digestive Disease Week®Yahoo Finance·Apr 22, 2026
- Abivax Annual Ordinary and Extraordinary General Meeting of May 11, 2026 Availability of the Preparatory DocumentsYahoo Finance·Apr 20, 2026
- Bright Prospects Ahead for Abivax (ABVX)Yahoo Finance·Apr 17, 2026
- ABIVAX (ABVX) Appoints Michael Nesrallah as Chief Commercial OfficerYahoo Finance·Apr 12, 2026
- Crohn's Disease Eight-Market Drug Forecast and Market Analysis Report 2025-2026: Novel MOAs Will Provide Market Shifts Throughout the Forecast Period to 2032GlobeNewswire Inc.·Apr 10, 2026
- This Beaten-Down Drug Stock Is Down Over 10% -- Is It Finally a Buy?Motley Fool·Apr 7, 2026
- Is ABIVAX (ENXTPA:ABVX) Pricing Reflect Its Sharp Multi‑Year Share Price SurgeYahoo Finance·Apr 5, 2026
- ABIVAX SA (ABVX) Surged by 58% in Q4Yahoo Finance·Apr 2, 2026
- Abivax Publishes Financial Reports with the French and U.S. Securities Regulatory AgenciesYahoo Finance·Apr 1, 2026
- 2 Healthcare Stocks That Could Soar Over the Next 5 YearsMotley Fool·Mar 26, 2026
- Abivax CEO Downplays Sale Talk, Eyes Capital Raise As Key Trial Data Readout NearsBenzinga·Mar 24, 2026
- Abivax Announces Full Year 2025 Financial Results and Provides Business UpdatesYahoo Finance·Mar 23, 2026
- 2 Healthcare Stocks to Buy Before They Get Bought OutMotley Fool·Mar 20, 2026
- This Investor Sold $104 Million of Nuvalent Stock Amid Cancer Drug Developer's Nearly 30% RallyMotley Fool·Mar 17, 2026
- This Biotech Attracted a $181 Million Investment During a Staggering 1,300% Stock RallyMotley Fool·Mar 17, 2026
- This Fund Bought $28 Million of a Beaten-Down Immunotherapy Stock Last Quarter. What Should Long-Term Investors Know?Motley Fool·Mar 16, 2026
- This $64 Million Biotech Exit Seemingly Missed a 77% One-Day Surge on Gilead Takeover DealMotley Fool·Mar 16, 2026
- Biotech Stock Up Nearly 300% Draws $68.7 Million Bet as Breast Cancer Drug Targets 2027 LaunchMotley Fool·Mar 16, 2026
- This Biotech Stock Up 700% Is Still a Top Holding Despite a $9.3 Million Sale Last QuarterMotley Fool·Mar 16, 2026
All 23 articles loaded
Price Data
52-Week Range
$126.54
Fundamentals
Trading
About Abivax
Abivax SA is a clinical-stage biotechnology company dedicated to developing groundbreaking immunotherapies for chronic inflammatory diseases and viral infections, leveraging its lead candidate ABX464, currently undergoing clinical trials for ulcerative colitis and other indications. The firm employs a unique combination of antibody-mediated therapies and proprietary compounds to address significant unmet medical needs, positioning itself favorably within the healthcare landscape. With a promising pipeline and a skilled scientific team committed to innovation, Abivax represents a compelling investment opportunity for institutional stakeholders looking to capitalize on advancements in the immunotherapy sector.